SEQUAR SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction

Sponsor
Karolinska Institutet (Other)
Overall Status
Recruiting
CT.gov ID
NCT04295148
Collaborator
(none)
200
1
2
70.7
2.8

Study Details

Study Description

Brief Summary

Randomized control trial comparing two different Anterior Cruciate Ligament (ACL) grafts in Anterior Cruciate Ligament Reconstruction: the semitendinosus hamstrings graft and the quadriceps graft. Capio Artro Clinic (Stockholm) has vast experience in ACL surgery using both semitendinosus and quadriceps grafts.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ACL Reconstruction with Semitendinosus graft
  • Procedure: ACL Reconstruction with Quadriceps tendon-bone graft
N/A

Detailed Description

The purpose of the study is to evaluate the quadriceps graft with bone-plug in Anterior Cruciate Ligament Reconstruction (ACL-R) and compare it with Sweden's standard choice of graft, semitendinosus graft in ACL-R in higher level athletes with Tegner Activity Scale 7 or higher. Both methods are well-known and continually registered in the Swedish ACL Registry. Patients will be followed up during a 2-year period.

Both grafts will be compared post operatively as to laxity, PROM, as well as measure graft site morbidity, Return to Sports rate, and the post-operative rehab. At 9 months we will also preform a MRI scan to determine graft maturity. 5-year and 10-year data will also be acquired through the Swedish ACL-registry and Lysholm score and Tegner Activity Level score. At 10-year a plain weight baring X-ray will be preformed to evaluate development of osteoarthritis.Both methods are well-known and continually registered in the Swedish ACL Registry.

The study design is a prospective randomized study with equal groups:

Semitendinosus graft (=100) and Quadriceps tendon graft (n=100). According to historical material from Capio Artro Clinic (Stockholm) the following power calculation has been made: Significance lever 5 percent (p=0.05) and power is 80%. The difference between the groups is 1 mm knee laxity with KT-1000 which would give an effect size of 0,44 or less compared to an average effect size (0,50). 85 individuals will be needed in each group in the statistical analysis. Stratifying according to gender will be done with 40% female and 60 % males, as this represent the prevalence of ACL reconstruction in our clinic and in the Swedish ACL registry. It is known the females have a higher rerupture rate and lower subjective outcome. Inclusion will continue until we have 100 individuals in each group according to the stratification. This means that each group can have more than 100 individuals. Randomization process and study design will be done according to the CONSORT guidelines.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
SEQUAR - SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction - a Prospective Randomized Study
Actual Study Start Date :
Feb 10, 2020
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Semitendinosus graft

Participants receive the Semitendinosus Graft technique during ACL reconstruction.

Procedure: ACL Reconstruction with Semitendinosus graft
Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
Other Names:
  • ACL-R with Semitendinosus graft
  • Semitendinosus ACL-R
  • Active Comparator: Quadriceps tendon-bone graft

    Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.

    Procedure: ACL Reconstruction with Quadriceps tendon-bone graft
    Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
    Other Names:
  • ACL-R with Quadriceps tendon-bone graft
  • Quad tendon-bone ACL-R
  • Outcome Measures

    Primary Outcome Measures

    1. Change from Baseline KT-1000 Knee Laxity at 6 months [Pre-operative appointment and 6 months post-operative appointments]

      The KT-1000 measures laxity objective- and parametrically and is a validated tool for establishing joint laxity post operatively in mm.

    2. Change from Baseline KOOS (the Knee Injury and Osteoarthritis Outcome Score) at 24 months [Pre-operative appointment and 24 months]

      Patients will complete the KOOS surveys at pre-operatively and at 2 years time post-operatively to evaluate subjective knee function

    Secondary Outcome Measures

    1. IKDC [Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments]

      Patients will complete the IKDC at specific time points to evaluate subjective knee function throughout treatment.

    2. PAS [Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments]

      Patients will complete the PAS at specific time points to evaluate subjective knee function throughout treatment

    3. KOOS [Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments]

      Patients will complete the KOOS at specific time points to evaluate subjective knee function throughout treatment

    4. EQ5D [Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments]

      Patients will complete the EQ5D at specific time points to evaluate subjective knee function throughout treatment

    5. Lysholm score [Pre-operative appointment, 6 months, 9 months, 12 months, 18 months, 24 months, 5 years and 10 years post-operative appointments]

      Patients will complete the Lysholm score at specific time points to evaluate subjective knee function throughout treatment

    6. Tegner Activity Score [Pre-operative appointment, 6 months, 9 months, 12 months, 18 months, 24 months, 5 years and 10 years post-operative appointments]

      Patients will complete the Tegner Activity score at specific time points to evaluate level of sports activity postoperatively.

    7. ACL-RSI [6 months and 12 months, post-operative appointments]

      Patients will complete the ACL-RSI surveys at specific time points to evaluate self efficacy and readiness to return to sports throughout treatment

    8. Return to Sports Questionnaire [6 months, 9 months and 12 months, 18 months, and 24 months post-operative appointments]

      Patients will complete the a Return to Sports Questionnaire at specific time points to evaluate return to sports after 6 and 12 months throughout treatment

    9. Werner anterior knee pain score [6 weeks, 6 months, 9 months, and 12 months]

      Patients will complete Werner anterior knee pain scores at specific time points to evaluate graft site pain/morbidity throughout treatment

    10. Kartus anterior knee pain score [6 weeks, 6 months, 9 months, and 12 months]

      Patients will complete Kartus anterior knee pain score at specific time points to evaluate graft site pain/morbidity throughout treatment

    11. Graft site morbidity questionnaire [6 weeks, 6 months, 12 months, 24 months]

      Patients will complete additional survey questions at specific time points to evaluate graft site pain/morbidity throughout treatment

    12. Goniometric measurement: Knee extension and flexion [2 weeks, 6 weeks, 6 months, 9 months and 12 months]

      Patients will undergo goniometric measurement at specific time points to evaluate knee moment throughout treatment.

    13. Measurement of circumference of the knee [2 weeks, 6 weeks, 6 months, 9 months and 12 months]

      Circumference of the knee will be measured at mid-patella and 15 cm above superior border of the patella. They will be compared with the contralateral knee to compare knee swelling.

    14. Biodex Isokinetic Measurement [6 months and 12 months]

      Patients will undergo Biodex Isokinetic measurement at specific time points to muscle strength throughout treatment.

    15. Functional knee tests [6 months, 9 months and 12 months]

      Patients will undergo functional knee test (ie one legged jump and crossover jump) at specific time points to evaluate functional knee movement throughout treatment.

    16. Lachmans test [Pre-operative appointment , 6 months, 9 months and 12 months]

      Patients will undergo passive accessory stability tests Lachmans test (graded 0,1,2 and 3) at specific time points to evaluate passive knee laxity throughout treatment.

    17. Pivot shift test [Pre-operative appointment , 6 months, 9 months and 12 months]

      Patients will undergo passive accessory stability tests pivot shift test (graded 0,1,2 and 3) at specific time points to evaluate passive knee laxity throughout treatment.

    18. Time to Return to Sports Rates [6 months, 9 months, 12 months, 18 months, 24 months]

      Time to return to sports will be evaluated through Return to Sport surveys at specific time points throughout treatment

    19. Graft failure rate or ACL re-rupture [10 years]

      ACL reconstruction will be evaluated by graft failure rate or ACL re-rupture during a 10 year period

    20. ACL re-operation [10 years]

      ACL reconstruction will be evaluated by re-operation rate during a 10 year period

    21. Graft maturity [9 months]

      Graft maturity after ACL reconstruction will be evaluated by MRI at 9 months postoperatively.

    22. 10 year X-Ray [10 years]

      Development of osteoarthritis after ACL reconstruction will be evaluated by plain weight baring X-rays at 10 years.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 40 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Primary ACL reconstruction for patients with Tegner score equal or higher than 7 before injury.
    Exclusion Criteria:
    • Multiligament knee injury

    • Former knee operation

    • Former fracture

    • Inflammatory disease

    • More than one ligamentous injury in the same knee requiring reconstructive surgery

    • Former ACL injury in the contralateral knee

    • Reconstruction of ACL in the contralateral knee during the study follow up period

    • Lack av baseline pre- or postoperative data (KT-1000, KOOS, Lysholm Score, EQ-5D)

    • Any other situation preventing patient from participating in extensive follow up.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Capio Artro Clinic AB Stockholm Sweden 11428

    Sponsors and Collaborators

    • Karolinska Institutet

    Investigators

    • Principal Investigator: Anders Stålman, MD,PhD, Karolinska Institutet
    • Principal Investigator: Mikael Östin, MD, Capio Artro Clinic AB
    • Principal Investigator: Vasileios Sarakatsianos, MD, Karolinska Institutet
    • Principal Investigator: Joanna Kvist, PhD, Karolinska Institutet
    • Principal Investigator: Daniel Castellanos, MD, Örebro University, Sweden

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anders Stalman, Senior Consultant, Principal Investigator, Ph.D., Karolinska Institutet
    ClinicalTrials.gov Identifier:
    NCT04295148
    Other Study ID Numbers:
    • DNR 2019-03359
    First Posted:
    Mar 4, 2020
    Last Update Posted:
    Sep 2, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 2, 2021